From Discovery to Deals: The Neurological Oligonucleotide Landscape at a Glance

Why This Neurological Oligonucleotide Data Is Essential

This presentation is your competitive advantage. Here’s what you’ll gain access to:

Preclinical, Clinical & Regulatory Insights

• Of 2,270 oligonucleotide therapies in development, 44% target neurological disorders, highlighting the central role CNS plays in this modality.
• The neurological pipeline is led by targets such as DMD, HTT, and SOD1, alongside other high-interest genes driving R&D focus.
• Regulatory momentum is building: Dyne Therapeutics’ DYNE-101 has received Breakthrough Therapy and Fast Track Designation for MDT1, setting a precedent for future oligonucleotide approvals.

Oligonucleotide Deal-Making & Collaborations

• Oligonucleotide partnerships continue to concentrate on neurology, with 27 collaborations focused on CNS disorders.
• Deal-making underscores investor and developer confidence in the therapeutic potential of oligonucleotides for neurological disease.

Company & Pipeline Landscape

• More than 560 active biopharma companies in the RNA space have at least one RNA-based therapeutic in preclinical development.
• While most are focused on mRNA and RNAi, oligonucleotide developers are rapidly advancing their presence in neurology.